Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01151761
Other study ID # HEP0032
Secondary ID HEP0032
Status Terminated
Phase Phase 2
First received June 15, 2010
Last updated December 12, 2012
Start date January 2011
Est. completion date July 2012

Study information

Verified date December 2012
Source Stanford University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine progression-free survival at 12 months for stereotactic body radiotherapy (SBRT) and chemotherapy for unresectable hilar cholangiocarcinoma (CCA).

Investigators hope to learn more about neoadjuvant SBRT and chemotherapy for unresectable CCA, and if SBRT followed by chemotherapy can lead to successful liver transplantation. This knowledge is important for this patient group as this disease is a highly lethal malignancy that often presents as unresectable, however surgery or transplantation are the only curative options.


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date July 2012
Est. primary completion date April 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Diagnosis of cholangiocarcinoma by any of the below:

- Positive transcatheter biopsy or brush cytology

- CA 19-9 ≥ 100mg/mL with a malignant-appearing stricture on cholangiography

- Biliary ploidy by fluorescent in situ hybridization with a malignant stricture on cholangiography

- Liver tumors not to exceed 8 cm in greatest axial dimension (800 cc of uninvolved liver)

- Unresectable tumor above cystic duct

- Hepatic lesion in patients for whom surgical resection is not possible or would not result in an opportunity for cure by any of the below:

- Bilateral segmental ductal extension

- Encasement of the main portal vein

- Unilateral segmental ductal extension with contralateral vascular encasement

- Unilateral atrophy with either contralateral segmental ductal or vascular (hepatic artery, portal vein) involvement

- Ascites is allowed if the Model for End-Stage Liver Disease (MELD) score is <15[1]

- Age > 18 years old

- Eastern Clinical Oncology Group performance status 0, 1 or 2 (Appendix 1)

- Lab values within 2 wks prior to randomization:

- See STUDY SCHEMA for specific blood count inclusion criteria: ANC ≥ 500 x 109/L (≥ 1500/mm3), Platelets ≥ 5 x 109/L (≥ 50,000/mm3), Hgb ≥ 9g/dL

- Adequate liver function: Total bilirubin ≤1.5 x upper limit of normal (ULN); ALT and/or AST & alkaline phosphatase ≤ 5 x ULN.

- Adequate biliary drainage, with no evidence of active uncontrolled infection (patients on antibiotics are eligible).

- See STUDY SCHEMA for specific renal function inclusion criteria: Adequate renal function with a calculated GFR ≥ 40 ml/min. If the calculated GFR is below 40 ml/min a 24 hour urine creatinine clearance can be used.

- Albumin > 2.5 mg/dL

- INR ≤ 1.5

- Life expectancy > 6 months

- Capable of giving written informed consent

Exclusion Criteria:

- Prior radiotherapy to the upper abdomen

- Contraindication to receiving radiotherapy

- Prior chemotherapy

- Prior biliary resection or attempted resection

- Prior transperitoneal biopsy

- Large esophageal varices without band ligation

- Active GI bleed or within 2 weeks of study enrollment

- Ascites refractory to medical therapy or shunting

- Active/unresolved biliary tract obstruction

- Presence of multifocal, lymphatic, or extrahepatic metastases

- Participation in another concurrent treatment protocol

- If history of other primary cancer, subject eligible only if she or he has:

- Curatively resected non-melanomatous skin cancer

- Curatively treated cervical carcinoma in situ

- Other primary solid tumor curatively treated with no known active disease present and no treatment administered for the last 3 years

- Any evidence of severe or uncontrolled systemic diseases or laboratory finding that in the view of the investigator makes it undesirable for the patient to participate in the trial

- Any psychiatric or other disorder (eg brain metastases) likely to impact on informed consent

- Pregnancy or breast-feeding

- While not excluded, patients with significant impaired hearing must be made aware of potential ototoxicity and may choose not to be included. If included, baseline audiograms are recommended and, in those given cisplatin, should be followed by repeat audiograms prior to cycle 2.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Procedure:
Stereotactic Body Radiotherapy
Standard of care
Drug:
Gemcitabine100 mg/m2
100 mg/m2, IV
Cisplatin
25 mg/m2, IV
Carboplatin
AUC 2, based on Calvert formula, IV
Capecitabine
1000 mg/m2, PO
5FU
200 mg/m2

Locations

Country Name City State
United States Stanford University School of Medicine Stanford California

Sponsors (1)

Lead Sponsor Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free survival at 12 months defined in Section 9.4 12 months No
Secondary Pathologic complete response rate as defined in Section 9.1.6 12 months No
Secondary Serum CA 19-9 levels defined in Section 9.1.7 12 months No
Secondary Adverse event rate as defined in Section 6.2.1 12 months No
Secondary Overall survival at 12 months defined in Section 9.1.2 12 months No
Secondary Liver transplant rate as defined in Section 9.1.4 12 months No
Secondary Freedom from local progression at 12 months as defined in Section 9.1.3 12 months No
Secondary Liver transplant conversion rate as defined in Section 9.1.5 12 months No
See also
  Status Clinical Trial Phase
Completed NCT03213314 - HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies N/A
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Completed NCT03756597 - PAN-study: Pan-Cancer Early Detection Study (PAN)
Recruiting NCT05160740 - Indocyanine Green Molecular Fluorescence Imaging Technique Using in Diagnosis and Treatment of Primary Liver Cancer N/A
Completed NCT01906021 - Study of New Software Used During Ablations N/A
Terminated NCT04589884 - Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment
Recruiting NCT05953337 - Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC) N/A
Enrolling by invitation NCT04466124 - Prospective Cohort Study of Liver Cancer Patients Treated With Proton Beam Therapy
Not yet recruiting NCT04053231 - Hepatocarcinoma Recurrence on the Liver Study - Part2
Active, not recruiting NCT02869217 - Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors Phase 1
Completed NCT03059238 - Parecoxib Versus Celecoxib Versus Oxycodone in Pain Control for Transcatheter Chemoembolization Procedure Phase 3
Recruiting NCT02632188 - Radical Surgery Followed by Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen for the Treatment of Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT01388101 - Real-time Diagnosis of Serum LECT 2 in Patient With Liver Cancer Using Electronic Antibody Sensor (e- Ab Sensor) N/A
Completed NCT01042041 - Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer Phase 1
Completed NCT00980239 - HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver Phase 1
Terminated NCT00903396 - Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer Phase 2
Completed NCT00790569 - Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking N/A
Terminated NCT00896467 - Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy N/A
Completed NCT00543777 - Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease Phase 1/Phase 2